Skip to main content
. 2021 Jan 29;11:611549. doi: 10.3389/fimmu.2020.611549

Figure 1.

Figure 1

(A) The patient under mycophenolate-mofetil 2 g/day and topical corticosteroids (before therapy with dupilumab and omalizumab), (B) 2 months after addition of omalizumab therapy to his therapy protocol, (C) stable clinical results, 3 months after addition of dupilumab to his therapy protocol.